|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
3/6/2012 8:43:16 AM
BERWYN, Pa.--(BUSINESS WIRE)--QR Pharma, Inc. (QR) a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease, Parkinson’s disease (PD) and other neurodegenerative disorders, announced today that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded the company $468,000 to conduct research for the development of Posiphen® to treat PD. QR will collaborate with Robert Nussbaum, MD, Professor, Department of Medicine and Chief, Division of Medical Genetics at the University of California, San Francisco and Jack T. Rogers, PhD, Associate Professor Psychiatry (Neuroscience) at the Massachusetts General Hospital, Genetics and Aging Research Unit.
|
|
|
|
|
|
|
|
|
|
|